New pill shows promise for Hard-to-Treat blood cancers
NCT ID NCT05024045
First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tumors. Some patients may also receive a second drug, pirtobrutinib. The study lasts up to about 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LOXO-338 (a BCL-2 inhibitor) taken by mouth, sometimes combined with pirtobrutinib
- What this could lead to
- If this works, it could offer a new treatment option for people with advanced blood cancers who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not prove safe or effective. Side effects are unknown, and the study is small and not designed to confirm benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Montpellier-Hopital St Eloi
Montpellier, 34295, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, Cedex, 69495, France
-
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
Nantes, 44093, France
-
Centre hospitalier universitaire de Haut Leveque
Pessac, 33604, France
-
Centrum Medyczne Pratia Poznan
Skorzewo, Poznan, 60 185, Poland
-
City of Hope National Medical Center
Duarte, California, 91010-0269, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
IRCCS - AOU di Bologna
Bologna, 40138, Italy
-
Indiana Blood & Marrow Transplantation (IBMT)
Indianapolis, Indiana, 46237, United States
-
Institut Curie
Paris, 75248, France
-
L'Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, Cedex 9, 31100, France
-
Mayo Clinic
Rochester, Minnesota, 55905-0002, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, 02-781, Poland
-
Pratia MCM Krakow
Krakow, 30-510, Poland
-
Swedish Medical Center
Seattle, Washington, 98104, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of California San Francisco, Medical Center at Paranassus
San Francisco, California, 94117, United States
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas